GRAIL (NASDAQ:GRAL) Receives Sell (D-) Rating from Weiss Ratings

GRAIL (NASDAQ:GRAL)‘s stock had its “sell (d-)” rating reiterated by investment analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently weighed in on GRAL. Canaccord Genuity Group raised their price target on GRAIL from $43.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. UBS Group set a $75.00 price target on GRAIL in a research report on Friday, October 3rd. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $56.67.

GRAIL Stock Performance

Shares of GRAL stock opened at $72.79 on Wednesday. GRAIL has a 52-week low of $12.57 and a 52-week high of $73.74. The company has a market capitalization of $2.62 billion, a PE ratio of -5.55 and a beta of 4.11. The business’s fifty day moving average is $40.51 and its 200 day moving average is $37.89.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%.The business had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $37.57 million. On average, sell-side analysts forecast that GRAIL will post -15.15 EPS for the current fiscal year.

Insider Transactions at GRAIL

In other news, CFO Aaron Freidin sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $38.93, for a total transaction of $311,440.00. Following the transaction, the chief financial officer directly owned 286,020 shares of the company’s stock, valued at approximately $11,134,758.60. This trade represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Joshua J. Ofman sold 81,385 shares of the firm’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $62.50, for a total value of $5,086,562.50. Following the transaction, the president directly owned 396,797 shares in the company, valued at $24,799,812.50. This trade represents a 17.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 103,279 shares of company stock worth $6,152,839 over the last ninety days. Insiders own 1.85% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GRAL. Wealthquest Corp purchased a new position in shares of GRAIL during the 1st quarter worth approximately $18,247,000. AQR Capital Management LLC grew its holdings in shares of GRAIL by 61.0% during the 1st quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company’s stock worth $33,991,000 after acquiring an additional 506,440 shares during the period. Geode Capital Management LLC grew its holdings in shares of GRAIL by 60.4% during the 2nd quarter. Geode Capital Management LLC now owns 757,770 shares of the company’s stock worth $38,969,000 after acquiring an additional 285,331 shares during the period. Carnegie Investment Counsel purchased a new position in shares of GRAIL during the 2nd quarter worth approximately $8,520,000. Finally, Invesco Ltd. grew its holdings in shares of GRAIL by 259.1% during the 2nd quarter. Invesco Ltd. now owns 218,671 shares of the company’s stock worth $11,244,000 after acquiring an additional 157,780 shares during the period.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.